Our mission is to improve precision medicine in neurodegeneration.
The Prominent project is supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112145. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio MedTech Europe, Vaccines Europe, BioArctic AB and Combinostics Oy.
Check out our March 2025 newsletter! It includes updates on the European Alzheimer's Alliance, our upcoming Annual Conference in Bologna #35AEC, the disappointing negative opinion of the European Medicines Agency on donanemab, and much more. Read it here: https://lnkd.in/dSbyW94e
On 28 March 2025, the Committee for Medicinal Products for Human use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the marketing authorisation application of Eli Lilly for donanemab for slowing the progression of Alzheimer’s disease.
This was followed by responses of European key stakeholders such as Alzheimer Europe, identifying several areas of concern including health inequity and patient autonomy. In their response to the decision, Alzheimer Europe highlighted possibilities for risk management and safety monitoring which could help protect patients at risk of side effects, whilst providing treatment to those who are most likely to benefit. Alzheimer Europe also underscored the value of real-world findings that could be gained through patient registries via the collection of real-world data on the use of these innovative medicines in other regions such as China, Japan, the United Kingdom (UK) and the United States (US), so that healthcare systems can learn and adapt to enable equitable access.
The Innovative Health Initiative (IHI)-funded IHI-PROMINENT project addresses several concerns raised by Alzheimer Europe. Through the development of Artificial Intelligence (AI)-based tools, PROMINENT could help clinicians identify patients at higher risk of side effects, such as amyloid-related imaging abnormalities (ARIA), including brain bleeds, which are particularly prevalent in patients with certain genetic profiles. Additionally, the project's platform would allow for the collection of real-world data outside of clinical trials, enabling close monitoring of adverse treatment effects and thereby inform future decisions about what specific patient profiles may be at risk of side effects.
Last but not least, PROMINENT's tools support the improvement of clinical pathways by reducing the amount of tests needed for an accurate diagnosis, thereby relieving healthcare costs and contributing to ensure equitable access to new therapies across Europe.
Give us a follow and stay up-to-date on our work and the future developments in progressing precision medicine in Alzheimer's disease and neurodegeneration.
A special thanks to Hanneke Rhodius- Meester from Amsterdam UMC & Oslo University Hospital for sharing her observations!
https://lnkd.in/emuQf9mzhttps://lnkd.in/enQDg8t5
We are looking for a talented Post Doctorate Scientist for a very exciting project where you will artificial intelligence algorithms for the analysis of clinical images. This is a great opportunity to work on state-of-the-art algorithms, on unique datasets and in a fantastic work environment!
